Tapewire

Nasdaq · USD

TVTX

Travere Therapeutics, Inc.

Export transactions ↓
Tapewire entity
1562
SEC CIK
0001438533
Parsed reports
437

Last 12 months

Inside the activity.

0 purchase rows · 116 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202506
Jan 202605
Feb 2026017
Mar 202601
Apr 2026023
May 2026015
Jun 202602
Jul 202600
Aug 202605
Sep 2026041
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
November 21, 2016 Filed Nov 23, 2016 21:25 UTC
ASELAGE STEVEDirector · Chief Executive Officer
SaleCommon Stock 5,000 $21.00 $105,000.00
Disclosure

SEC source: 0001209191-16-151969 · doc4.xml · nonDerivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,756

Read SEC document
November 21, 2016 Filed Nov 23, 2016 21:25 UTC
ASELAGE STEVEDirector · Chief Executive Officer
GiftCommon Stock 57,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-151969 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,756

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.